Next-Generation Breast Cancer Diagnostic and Screening Market - Global Outlook and Forecast 2021-2027
This report contains market size and forecasts of Next-Generation Breast Cancer Diagnostic and Screening in Global, including the following market information:
Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Next-Generation Breast Cancer Diagnostic and Screening market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Next-Generation Breast Cancer Diagnostic and Screening companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Next-Generation Breast Cancer Diagnostic and Screening Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Type, 2020 (%)
China Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Application, 2020 (%)
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Region and Country, 2020 (%)
The report also provides analysis of leading market participants including:
Total Next-Generation Breast Cancer Diagnostic and Screening Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Next-Generation Breast Cancer Diagnostic and Screening Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Next-Generation Breast Cancer Diagnostic and Screening market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Next-Generation Breast Cancer Diagnostic and Screening companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Next-Generation Breast Cancer Diagnostic and Screening Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Type, 2020 (%)
- Real-Time PCR (q-PCR)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Fluorescent In-Situ Hybridization (FISH)
China Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Application, 2020 (%)
- Hospital-associated Labs
- Cancer Research Institutes
- Diagnostic Centers
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Region and Country, 2020 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Total Next-Generation Breast Cancer Diagnostic and Screening Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Next-Generation Breast Cancer Diagnostic and Screening Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
- Abbott Laboratories
- Agendia
- Agilent Technologies
- Ambry Genetics
- Biocept
- Biotheranostics
- Centogene
- Danaher Corporation
- EXACT Sciences Corporation
- Roche Holding AG
- Fulgent Genetics
- Illumina
- Invitae
- Lucence Diagnostics Pte Ltd
- Myriad Genetics
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Next-Generation Breast Cancer Diagnostic and Screening Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC AND SCREENING OVERALL MARKET SIZE
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2021 VS 2027
2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
3.2 Top Global Next-Generation Breast Cancer Diagnostic and Screening Companies Ranked by Revenue
3.3 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies
3.4 Top 3 and Top 5 Next-Generation Breast Cancer Diagnostic and Screening Companies in Global Market, by Revenue in 2020
3.5 Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type
3.6 Tier 1, Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
3.6.1 List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies
3.6.2 List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Markets, 2021 & 2027
4.1.2 Real-Time PCR (q-PCR)
4.1.3 Immunohistochemistry (IHC)
4.1.4 Next-Generation Sequencing (NGS)
4.1.5 Fluorescent In-Situ Hybridization (FISH)
4.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
4.2.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2021
4.2.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2022-2027
4.2.3 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2021 & 2027
5.1.2 Hospital-associated Labs
5.1.3 Cancer Research Institutes
5.1.4 Diagnostic Centers
5.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
5.2.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2021
5.2.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2022-2027
5.2.3 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
6 SIGHTS BY REGION
6.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2021 & 2027
6.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
6.2.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2021
6.2.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2022-2027
6.2.3 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.3.2 US Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.4.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.4 U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.5 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.6 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.7 Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.8 Benelux Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.5.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.5 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.6 India Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.6.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.6.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.7.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7.3 Israel Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7.4 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7.5 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
7 PLAYERS PROFILES
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Corporate Summary
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.1.5 Abbott Laboratories Key News
7.2 Agendia
7.2.1 Agendia Corporate Summary
7.2.2 Agendia Business Overview
7.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.2.5 Agendia Key News
7.3 Agilent Technologies
7.3.1 Agilent Technologies Corporate Summary
7.3.2 Agilent Technologies Business Overview
7.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.3.5 Agilent Technologies Key News
7.4 Ambry Genetics
7.4.1 Ambry Genetics Corporate Summary
7.4.2 Ambry Genetics Business Overview
7.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.4.5 Ambry Genetics Key News
7.5 Biocept
7.5.1 Biocept Corporate Summary
7.5.2 Biocept Business Overview
7.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.5.5 Biocept Key News
7.6 Biotheranostics
7.6.1 Biotheranostics Corporate Summary
7.6.2 Biotheranostics Business Overview
7.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.6.5 Biotheranostics Key News
7.7 Centogene
7.7.1 Centogene Corporate Summary
7.7.2 Centogene Business Overview
7.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.4.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.7.5 Centogene Key News
7.8 Danaher Corporation
7.8.1 Danaher Corporation Corporate Summary
7.8.2 Danaher Corporation Business Overview
7.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.8.5 Danaher Corporation Key News
7.9 EXACT Sciences Corporation
7.9.1 EXACT Sciences Corporation Corporate Summary
7.9.2 EXACT Sciences Corporation Business Overview
7.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.9.5 EXACT Sciences Corporation Key News
7.10 Roche Holding AG
7.10.1 Roche Holding AG Corporate Summary
7.10.2 Roche Holding AG Business Overview
7.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.10.5 Roche Holding AG Key News
7.11 Fulgent Genetics
7.11.1 Fulgent Genetics Corporate Summary
7.11.2 Fulgent Genetics Business Overview
7.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.11.5 Fulgent Genetics Key News
7.12 Illumina
7.12.1 Illumina Corporate Summary
7.12.2 Illumina Business Overview
7.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.12.5 Illumina Key News
7.13 Invitae
7.13.1 Invitae Corporate Summary
7.13.2 Invitae Business Overview
7.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.13.5 Invitae Key News
7.14 Lucence Diagnostics Pte Ltd
7.14.1 Lucence Diagnostics Pte Ltd Corporate Summary
7.14.2 Lucence Diagnostics Pte Ltd Business Overview
7.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.14.5 Lucence Diagnostics Pte Ltd Key News
7.15 Myriad Genetics
7.15.1 Myriad Genetics Corporate Summary
7.15.2 Myriad Genetics Business Overview
7.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.15.5 Myriad Genetics Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Next-Generation Breast Cancer Diagnostic and Screening Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC AND SCREENING OVERALL MARKET SIZE
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2021 VS 2027
2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
3.2 Top Global Next-Generation Breast Cancer Diagnostic and Screening Companies Ranked by Revenue
3.3 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies
3.4 Top 3 and Top 5 Next-Generation Breast Cancer Diagnostic and Screening Companies in Global Market, by Revenue in 2020
3.5 Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type
3.6 Tier 1, Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
3.6.1 List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies
3.6.2 List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Markets, 2021 & 2027
4.1.2 Real-Time PCR (q-PCR)
4.1.3 Immunohistochemistry (IHC)
4.1.4 Next-Generation Sequencing (NGS)
4.1.5 Fluorescent In-Situ Hybridization (FISH)
4.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
4.2.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2021
4.2.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2022-2027
4.2.3 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2021 & 2027
5.1.2 Hospital-associated Labs
5.1.3 Cancer Research Institutes
5.1.4 Diagnostic Centers
5.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
5.2.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2021
5.2.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2022-2027
5.2.3 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
6 SIGHTS BY REGION
6.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2021 & 2027
6.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
6.2.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2021
6.2.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2022-2027
6.2.3 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.3.2 US Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.4.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.4 U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.5 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.6 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.7 Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.4.8 Benelux Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.5.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.5 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.5.6 India Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.6.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.6.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027
6.7.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7.3 Israel Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7.4 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
6.7.5 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2016-2027
7 PLAYERS PROFILES
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Corporate Summary
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.1.5 Abbott Laboratories Key News
7.2 Agendia
7.2.1 Agendia Corporate Summary
7.2.2 Agendia Business Overview
7.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.2.5 Agendia Key News
7.3 Agilent Technologies
7.3.1 Agilent Technologies Corporate Summary
7.3.2 Agilent Technologies Business Overview
7.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.3.5 Agilent Technologies Key News
7.4 Ambry Genetics
7.4.1 Ambry Genetics Corporate Summary
7.4.2 Ambry Genetics Business Overview
7.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.4.5 Ambry Genetics Key News
7.5 Biocept
7.5.1 Biocept Corporate Summary
7.5.2 Biocept Business Overview
7.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.5.5 Biocept Key News
7.6 Biotheranostics
7.6.1 Biotheranostics Corporate Summary
7.6.2 Biotheranostics Business Overview
7.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.6.5 Biotheranostics Key News
7.7 Centogene
7.7.1 Centogene Corporate Summary
7.7.2 Centogene Business Overview
7.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.4.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.7.5 Centogene Key News
7.8 Danaher Corporation
7.8.1 Danaher Corporation Corporate Summary
7.8.2 Danaher Corporation Business Overview
7.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.8.5 Danaher Corporation Key News
7.9 EXACT Sciences Corporation
7.9.1 EXACT Sciences Corporation Corporate Summary
7.9.2 EXACT Sciences Corporation Business Overview
7.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.9.5 EXACT Sciences Corporation Key News
7.10 Roche Holding AG
7.10.1 Roche Holding AG Corporate Summary
7.10.2 Roche Holding AG Business Overview
7.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.10.5 Roche Holding AG Key News
7.11 Fulgent Genetics
7.11.1 Fulgent Genetics Corporate Summary
7.11.2 Fulgent Genetics Business Overview
7.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.11.5 Fulgent Genetics Key News
7.12 Illumina
7.12.1 Illumina Corporate Summary
7.12.2 Illumina Business Overview
7.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.12.5 Illumina Key News
7.13 Invitae
7.13.1 Invitae Corporate Summary
7.13.2 Invitae Business Overview
7.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.13.5 Invitae Key News
7.14 Lucence Diagnostics Pte Ltd
7.14.1 Lucence Diagnostics Pte Ltd Corporate Summary
7.14.2 Lucence Diagnostics Pte Ltd Business Overview
7.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.14.5 Lucence Diagnostics Pte Ltd Key News
7.15 Myriad Genetics
7.15.1 Myriad Genetics Corporate Summary
7.15.2 Myriad Genetics Business Overview
7.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (2016-2021)
7.15.5 Myriad Genetics Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Next-Generation Breast Cancer Diagnostic and Screening Market Opportunities & Trends in Global Market
Table 2. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers in Global Market
Table 3. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints in Global Market
Table 4. Key Players of Next-Generation Breast Cancer Diagnostic and Screening in Global Market
Table 5. Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Companies, 2016-2021
Table 8. Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type
Table 9. List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 30. Abbott Laboratories Corporate Summary
Table 31. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 32. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 33. Agendia Corporate Summary
Table 34. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 35. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 36. Agilent Technologies Corporate Summary
Table 37. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 38. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 39. Ambry Genetics Corporate Summary
Table 40. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 41. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 42. Biocept Corporate Summary
Table 43. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 44. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 45. Biotheranostics Corporate Summary
Table 46. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 47. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 48. Centogene Corporate Summary
Table 49. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 50. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 51. Danaher Corporation Corporate Summary
Table 52. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 53. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 54. EXACT Sciences Corporation Corporate Summary
Table 55. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 56. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 57. Roche Holding AG Corporate Summary
Table 58. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 59. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 60. Fulgent Genetics Corporate Summary
Table 61. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 62. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 63. Illumina Corporate Summary
Table 64. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 65. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 66. Invitae Corporate Summary
Table 67. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 68. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 69. Lucence Diagnostics Pte Ltd Corporate Summary
Table 70. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 71. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 72. Myriad Genetics Corporate Summary
Table 73. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 74. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 1. Next-Generation Breast Cancer Diagnostic and Screening Market Opportunities & Trends in Global Market
Table 2. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers in Global Market
Table 3. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints in Global Market
Table 4. Key Players of Next-Generation Breast Cancer Diagnostic and Screening in Global Market
Table 5. Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Companies, 2016-2021
Table 8. Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type
Table 9. List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022-2027
Table 30. Abbott Laboratories Corporate Summary
Table 31. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 32. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 33. Agendia Corporate Summary
Table 34. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 35. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 36. Agilent Technologies Corporate Summary
Table 37. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 38. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 39. Ambry Genetics Corporate Summary
Table 40. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 41. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 42. Biocept Corporate Summary
Table 43. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 44. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 45. Biotheranostics Corporate Summary
Table 46. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 47. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 48. Centogene Corporate Summary
Table 49. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 50. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 51. Danaher Corporation Corporate Summary
Table 52. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 53. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 54. EXACT Sciences Corporation Corporate Summary
Table 55. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 56. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 57. Roche Holding AG Corporate Summary
Table 58. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 59. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 60. Fulgent Genetics Corporate Summary
Table 61. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 62. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 63. Illumina Corporate Summary
Table 64. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 65. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 66. Invitae Corporate Summary
Table 67. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 68. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 69. Lucence Diagnostics Pte Ltd Corporate Summary
Table 70. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 71. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
Table 72. Myriad Genetics Corporate Summary
Table 73. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 74. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), (2016-2021)
LIST OF FIGURES
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Segment by Type
Figure 2. Next-Generation Breast Cancer Diagnostic and Screening Segment by Application
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2020
Figure 8. By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 9. By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 10. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 11. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 12. US Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 16. Germany Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 17. France Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 24. China Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 28. India Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 30. Brazil Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 33. Turkey Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 37. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 50. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 51. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Segment by Type
Figure 2. Next-Generation Breast Cancer Diagnostic and Screening Segment by Application
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2020
Figure 8. By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 9. By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 10. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 11. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 12. US Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 16. Germany Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 17. France Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 24. China Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 28. India Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 30. Brazil Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2016-2027
Figure 33. Turkey Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2016-2027
Figure 37. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 50. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 51. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
